These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21861543)

  • 1. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.
    Garnock-Jones KP
    Drugs; 2011 Aug; 71(12):1579-90. PubMed ID: 21861543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
    Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
    Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
    Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
    Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
    Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
    Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
    Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
    Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
    Guérin A; Chen L; Ionescu-Ittu R; Marynchenko M; Nitulescu R; Hiscock R; Keir C; Wu EQ
    Curr Med Res Opin; 2014 Nov; 30(11):2317-28. PubMed ID: 25025755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    McCormack PL; Keam SJ
    Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib.
    Plosker GL; Robinson DM
    Drugs; 2008; 68(4):449-59; discussion 460-1. PubMed ID: 18318563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
    Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
    Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
    Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
    Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
    Hochhaus A; Saglio G; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre PD; Etienne G; Dorlhiac-Llacer PE; Clark RE; Flinn IW; Nakamae H; Donohue B; Deng W; Dalal D; Menssen HD; Kantarjian HM
    Leukemia; 2016 May; 30(5):1044-54. PubMed ID: 26837842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
    Giles FJ; Rosti G; Beris P; Clark RE; le Coutre P; Mahon FX; Steegmann JL; Valent P; Saglio G
    Expert Rev Hematol; 2010 Dec; 3(6):665-73. PubMed ID: 21091142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.